Back to discover

Protein / target

V-set domain-containing T-cell activation inhibitor 1

Encoded byVTCN1Q7Z7D3Homo sapiensSwiss-Prot
UniProt: Q7Z7D3Ensembl: ENSG00000134258HGNC: HGNC:28873NCBI Gene: 79679
Antibody-tractable
Druggability
UniProt loc med conf
1
Research papers

Protein at a glance

Biological role

Signaling receptor binding

Strongest disease association

Alcohol drinking

Via encoding gene VTCN1 · Genetic evidence · score 0.57

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity.

View complete UniProt function annotation

Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation

Subcellular location

Cell membrane
Domains and Gene Ontology detail (10)

Domains & features

Ig-like V-type 1Ig-like V-type 2

Gene Ontology

  • Cexternal side of plasma membrane
  • Fsignaling receptor binding
  • Padaptive immune response
  • Pnegative regulation of apoptotic process
  • Pnegative regulation of T cell activation
  • Pnegative regulation of T cell proliferation
  • Pregulation of cytokine production
  • PT cell receptor signaling pathway

282 aa · 31 kDa · 4 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingUniProt · GO
View supporting evidence

Immune signalling

  • ·Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, pr…
  • ·adaptive immune response
  • ·negative regulation of T cell activation
  • ·negative regulation of T cell proliferation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene VTCN1

Gene-level evidence surfaced through the gene VTCN1 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Alcohol drinking
0.57Moderately supported

Genetic evidence dominant · Open Targets 0.35

Helicobacter Infections
0.45Limited support

Genetic evidence dominant · Open Targets 0.27

Kidney Diseases
0.39Limited support

Genetic evidence dominant · Open Targets 0.23

Carcinoma, Non-Small-Cell Lung
0.17Preliminary

Literature evidence dominant · Open Targets 0.11 · no direct causal or clinical evidence

Neoplasms
0.15Preliminary

Literature evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

View evidence synthesis (5)
Alcohol drinkingModerately supported
0.57
agreement 0.45–0.69
Genetic100%

Open Targets aggregate 0.35 · 1 independent evidence family

Helicobacter InfectionsLimited support
0.45
agreement 0.33–0.57
Genetic100%

Open Targets aggregate 0.27 · 1 independent evidence family

Kidney DiseasesLimited support
0.39
agreement 0.25–0.53
Genetic98%Literature2%

Open Targets aggregate 0.23 · 2 independent evidence families

Carcinoma, Non-Small-Cell LungPreliminary
0.17
agreement 0.00–0.36
Literature71%RNA expression29%

Open Targets aggregate 0.11 · 2 independent evidence families · no direct causal or clinical evidence

NeoplasmsPreliminary
0.15
agreement 0.00–0.42
Literature100%

Open Targets aggregate 0.12 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Alcohol drinking0.35
Helicobacter Infections0.27
Kidney Diseases0.23
Neoplasms0.12
Carcinoma, Non-Small-Cell Lung0.11
Carcinoma, Hepatocellular0.11

Tractability

Antibodies — Emerging

Feasibility evidence (uniprot loc med conf and uniprot sigp or tmhmm) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
AB · UniProt loc med confAB · UniProt SigP or TMHMMAB · GO CC med confAB · Human Protein Atlas loc

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.25 cites

Gitto SB · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

Recent

A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.

Gitto SB · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

Europe PMC papers linked directly to this protein.